NSCLC and Baseline Brain Metastases: Results from ASCEND-2 and ASCEND-3

Speaker: Sumitra Thongprasert

Two phase II studies assessing the efficacy and safety of ceritinib in patients with ALK rearranged NSCLC and baseline brain metastases were presented at ESMO Asia 2015 Congress in Singapore. The second generation ALK inhibitor showed a promising clinical activity both in ASCEND-2 and ASCEND-3. Commenting the top results, S Thongprasert states that ceritinib could be an effective strategy to control brain metastases in ALK-naive and patients previously treated with crizotinib .

Discussion Points

  • What is the study design for ASCEND-2? And what is the study design for ASCEND-3?
  • What are the main results from both studies in terms of efficacy and safety of ceritinib?
  • Did ceritinib show to be effective in brain metastasis in ALK-positive NSCLC patients? and to what extent?
  • What would be the possible impact of these results on clinical practice?